Table 1—

Baseline demographic data and characteristics of type 2 diabetic patients undergoing hemodialysis who received rosiglitazone and were included for effectiveness (n = 72) and safety (n = 78) evaluation

Age (years)56.8 ± 7.2
Sex (male:female)36:42
Duration on hemodialysis (months)28.2 ± 8.4
Kt/V1.62 ± 0.26
Existing hypoglycemic agent (%)28
Existing insulin (%)42
Physical measurements
    Systolic blood pressure (mmHg)134 ± 16
    Diastolic blood pressure (mmHg)86 ± 14
    Weight (kg)*57.4 ± 10.6
    BMI (kg/m2)24.2–33.6
CTR (%)48.2 ± 5.6
Biochemical parameters
    Fasting glucose level (mg/dl)142 ± 21
    A1C (%)8.6 ± 0.6
    Albumin (g/dl)3.8 ± 0.3
    Blood urea nitrogen (mg/dl)78 ± 16
    Creatinine (mg/dl)8.6 ± 1.6
    AST (IU/l)19.2 ± 5.4
    ALT (IU/l)13.4 ± 4.8
    Alkaline phosphatase (IU/l)75 ± 8.6
    Total cholesterol (mg/dl)178 ± 42.1
    Triglyceride (mg/dl)194 ± 112.5
    HDL cholesterol (mg/dl)36 ± 16
    LDL cholesterol (mg/dl)110 ± 23
Comorbidities
    Hypertension (%)46
    Coronary artery disease (%)26
    HBV (%)§15.4
    HCV (%)§16.7
    Smoking (%)9.1
  • Data are means ± SD or range unless otherwise indicated.

  • *

    * Weight, expressed as midweek predialysis weight (dry weight).

  • The CTR is the maximum transverse diameter of the heart divided by the greatest internal diameter of the thoracic cage (from inside of rib to inside of rib).

  • Hypertension was defined by midweek predialysis levels of blood pressure, measured at the hemodialysis unit, according to criteria of The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) or receipt of antihypertensive agents.

  • §

    § HBV is defined as patients with hepatitis B surface antigen-positive carrier status, and HCV is defined as patients with anti-HCV antibody.